No Data
Shareholders Should Be Pleased With Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Price
Hong Kong Stock Morning Report | Two departments encourage foreign investment to conduct Private Equity in China. Meituan will pay social insurance for full-time and stable part-time delivery riders.
① Two departments: Encouraging foreign investment to engage in Private Equity in China, guiding more high-quality foreign capital to invest long-term in our listed companies. ② State-owned Assets Supervision and Administration Commission: Accelerating the establishment of an evaluation system for state-owned enterprises to fulfill their Global Strategy missions. ③ Meituan: Will provide social insurance for full-time and stable part-time delivery riders. ④ Federal Reserve minutes: Interest rate cuts require further decline in inflation, and tariff policies add uncertainty.
Haohai Biotech: Shanghai Haohai Biotechnology Co., Ltd. 2024 Annual Performance Report Announcement
Shanghai Haohai Biotechnology Co., Ltd. 2024 Annual Results Express Announcement
Shanghai Haohai Biological Technology's net profit growth is weak in 2024, and the Industry is facing a period of performance pain.
① In terms of quarterly performance, Shanghai Haohai Biological Technology achieved a net income of 79.27 million yuan in the fourth quarter, a year-on-year decrease of 11.26% and a quarter-on-quarter decrease of 24.93%. ② The "Shanghai Haohai Biological Technology International Pharmaceutical Research and Development and Industrialization Project" has partially been put into use, and the production capacity for businesses like hyaluronic acid will gradually be released.
Shanghai Haohai Biological Technology Reports Stable Financial Performance for 2024
Investors Interested In Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Earnings
